SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.

Abstract

Receptor tyrosine kinases (RTK), such as vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), stem cell factor receptor (KIT), and fms-like tyrosine kinase 3 (FLT3), are expressed in malignant tissues and act in concert, playing diverse and major roles in angiogenesis, tumor growth, and metastasis. With the exception of a few malignancies, seemingly driven by a single genetic mutation in a signaling protein, most tumors are the product of multiple mutations in multiple aberrant signaling pathways. Consequently, simultaneous targeted inhibition of multiple signaling pathways could be more effective than inhibiting a single pathway in cancer therapies. Such a multitargeted strategy has recently been validated in a number of preclinical and clinical studies using RTK inhibitors with broad target selectivity. SU14813, a small molecule identified from the same chemical library used to isolate sunitinib, has broad-spectrum RTK inhibitory activity through binding to and inhibition of VEGFR, PDGFR, KIT, and FLT3. In cellular assays, SU14813 inhibited ligand-dependent and ligand-independent proliferation, migration, and survival of endothelial cells and/or tumor cells expressing these targets. SU14813 inhibited VEGFR-2, PDGFR-beta, and FLT3 phosphorylation in xenograft tumors in a dose- and time-dependent fashion. The plasma concentration required for in vivo target inhibition was estimated to be 100 to 200 ng/mL. Used as monotherapy, SU14813 exhibited broad and potent antitumor activity resulting in regression, growth arrest, or substantially reduced growth of various established xenografts derived from human or rat tumor cell lines. Treatment in combination with docetaxel significantly enhanced both the inhibition of primary tumor growth and the survival of the tumor-bearing mice compared with administration of either agent alone. In summary, SU14813 inhibited target RTK activity in vivo in association with reduction in angiogenesis, target RTK-mediated proliferation, and survival of tumor cells, leading to broad and potent antitumor efficacy. These data support the ongoing phase I clinical evaluation of SU14813 in advanced malignancies.

• Authors: Shem Patyna, A Douglas Laird, Dirk B Mendel, Anne-Marie O'farrell, Chris Liang, Huiping Guan, Tomas Vojkovsky, Stefan Vasile, Xueyan Wang, Jeffrey Chen, Maren Grazzini, Cheng Y Yang, Joshua O Haznedar, Juthamas Sukbuntherng, Wei-Zhu Zhong, Julie M Cherrington, Dana Hu-Lowe
• Journal: Molecular cancer therapeutics (Mol Cancer Ther) Vol. 5 Issue 7 Pg. 1774-82 (Jul 2006) ISSN: 1535-7163 [Print] United States
• PMID: 16891463 (Publication Type: Journal Article)

Chemical References

• 5-((5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl)-N-(2-hydroxy-3-morpholin-4-ylpropyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide
• Angiogenesis Inhibitors
• Antineoplastic Agents
• Indoles
• Morpholines
• Protein Kinase Inhibitors
• Receptor Protein-Tyrosine Kinases
• Receptor, Platelet-Derived Growth Factor beta
• Vascular Endothelial Growth Factor Receptor-2

Topics

• Angiogenesis Inhibitors (chemistry, pharmacology, therapeutic use)
• Animals
• Antineoplastic Agents (chemistry, pharmacology, therapeutic use)
• Cell Proliferation
• Humans
• Indoles (chemistry, pharmacology, therapeutic use)
• Mice
• Morpholines (chemistry, pharmacology, therapeutic use)
• Neoplasms (drug therapy, enzymology)
• Protein Kinase Inhibitors (chemistry, pharmacology, therapeutic use)
• Rats
• Receptor Protein-Tyrosine Kinases (antagonists & inhibitors)
• Receptor, Platelet-Derived Growth Factor beta (antagonists & inhibitors)
• Tumor Cells, Cultured
• Vascular Endothelial Growth Factor Receptor-2 (antagonists & inhibitors)
• Xenograft Model Antitumor Assays